A new review outlines how CAR-T development is shifting from a blood-cancer focus toward solid tumors with emphasis on engineered designs, biomarkers, manufacturing changes, and economics. The article maps emerging strategies intended to improve safety, increase persistence, and reduce production cost—key barriers to scaling cell therapy beyond hematologic malignancies.